MIV Therapeutics, a leading developer of new generation biocompatible coatings
and advanced drug delivery systems, recently announced that a pivotal long-term
animal study of its novel stent coating technology has been concluded, with
results that were unequivocally successful in demonstrating the coating's excellent
biocompatibility and safety. The 6-month study, performed by Center for Research
in Cardiovascular Interventions of the Methodist Hospital Research Institute,
an independent research organization, indicated that MIVT's Hydroxyapatite-based
coatings were excellent candidates for advanced drug-eluting stent coatings.